| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
137,030,000 |
| Market
Cap: |
6.22(B) |
| Last
Volume: |
1,037,269 |
Avg
Vol: |
1,220,880 |
| 52
Week Range: |
$32.43 - $44.03 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 466 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Halozyme Therapeutics is a biopharma technology platform company that provides solutions to improve patient experience and outcomes. Co.'s approved product and its collaborators' approved products and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. Co. refers to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as its ENHANZE® drug delivery technology (ENHANZE). Co. licenses the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
60,000 |
110,000 |
280,000 |
564,448 |
| Total Sell Value |
$2,402,413 |
$4,320,555 |
$11,408,715 |
$26,006,116 |
| Total People Sold |
1 |
1 |
3 |
6 |
| Total Sell Transactions |
6 |
11 |
28 |
59 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Labarre Michael J. |
SVP, Chief Technical Officer |
• – – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,883 |
169,376 |
|
- |
|
| Matsuda Masaru |
SVP, General Counsel |
• – – |
2020-02-12 |
4 |
D |
$20.00 |
$33,620 |
D/D |
(1,681) |
6,938 |
|
- |
|
| Matsuda Masaru |
SVP, General Counsel |
• – – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,130 |
8,619 |
|
- |
|
| Labarre Michael J. |
SVP, Chief Technical Officer |
• – – |
2020-02-03 |
4 |
D |
$19.21 |
$82,392 |
D/D |
(4,289) |
161,493 |
|
- |
|
| Labarre Michael J. |
SVP, Chief Technical Officer |
• – – |
2020-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,559 |
165,782 |
|
- |
|
| Torley Helen |
President and CEO |
• • – |
2020-02-03 |
4 |
D |
$19.21 |
$382,471 |
D/D |
(19,910) |
439,657 |
|
- |
|
| Torley Helen |
President and CEO |
• • – |
2020-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
55,487 |
459,567 |
|
- |
|
| Stelzer Laurie |
SVP, Chief Financial Officer |
• – – |
2020-02-03 |
4 |
D |
$19.21 |
$158,963 |
D/D |
(8,275) |
96,806 |
|
- |
|
| Stelzer Laurie |
SVP, Chief Financial Officer |
• – – |
2020-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,119 |
105,081 |
|
- |
|
| Matsuda Masaru |
SVP, General CounselOfficer |
• – – |
2020-01-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,489 |
|
35% |
|
| Labarre Michael J. |
SVP, Chief Technical OfficerOf |
• – – |
2020-01-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
154,223 |
|
35% |
|
| Hickey Benjamin |
SVP, Chief Commerical Officer |
• – – |
2019-10-01 |
4 |
D |
$15.46 |
$108,065 |
D/D |
(6,990) |
13,226 |
|
- |
|
| Hickey Benjamin |
SVP, Chief Commerical Officer |
• – – |
2019-10-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,216 |
20,216 |
|
- |
|
| Chondros Dimitrios |
SVP, Chief Medical Officer |
• – – |
2019-08-03 |
4 |
S |
$16.70 |
$22,178 |
D/D |
(1,328) |
38,584 |
|
- |
|
| Stelzer Laurie |
SVP, Chief Financial Officer |
• – – |
2019-06-15 |
4 |
D |
$15.73 |
$53,608 |
D/D |
(3,408) |
81,962 |
|
- |
|
| Stelzer Laurie |
SVP, Chief Financial Officer |
• – – |
2019-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
85,370 |
|
- |
|
| Chondros Dimitrios |
SVP, Chief Medical Officer |
• – – |
2019-06-01 |
4 |
D |
$14.75 |
$10,414 |
D/D |
(706) |
39,912 |
|
- |
|
| Chondros Dimitrios |
SVP, Chief Medical Officer |
• – – |
2019-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,043 |
40,618 |
|
- |
|
| Kelley Kenneth J |
Director |
– • – |
2019-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,173 |
224,924 |
|
- |
|
| Henderson Jeffrey William |
Director |
– • – |
2019-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,173 |
63,278 |
|
- |
|
| Connaughton Bernadette |
Director |
– • – |
2019-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,173 |
17,954 |
|
- |
|
| Bizzari Jean-Pierre |
Director |
– • – |
2019-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,173 |
73,485 |
|
- |
|
| Posard Matthew L. |
Director |
– • – |
2019-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,173 |
114,924 |
|
- |
|
| Matsui Connie |
Director |
– • – |
2019-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,173 |
239,924 |
|
- |
|
| Daly James M |
Director |
– • – |
2019-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,173 |
56,873 |
|
- |
|
496 Records found
|
|
Page 13 of 20 |
|
|
0.43 (0.94%) 
